Management of Stage II Germ Cell Tumors.

[1]  P. Albers,et al.  Retroperitoneal lymph node dissection in the setting of elevated markers , 2018, Current opinion in urology.

[2]  P. Albers,et al.  The PRIMETEST trial – interim results of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment , 2018 .

[3]  P. Warde,et al.  A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. , 2018, European urology focus.

[4]  T. Masterson,et al.  Modified retroperitoneal lymph node dissection for post‐chemotherapy residual tumour: a long‐term update , 2017, BJU international.

[5]  P. Pierorazio,et al.  Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. , 2017, European urology.

[6]  A. Jemal,et al.  Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. , 2016, Practical radiation oncology.

[7]  S. Beriwal,et al.  Stage II Testicular Seminoma: Patterns of Care and Survival by Treatment Strategy. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  Terukazu Nakamura,et al.  Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors , 2016, International Journal of Clinical Oncology.

[9]  L. Zaletel,et al.  Treatment-related Cardiovascular Toxicity in Long-term Survivors of Testicular Cancer , 2016, Radiology and oncology.

[10]  E. Castle,et al.  Robot‐assisted retroperitoneal lymph node dissection in testicular cancer , 2015, Journal of surgical oncology.

[11]  A. Horwich,et al.  Guidelines on Testicular Cancer: 2015 Update. , 2015, European urology.

[12]  F. Bladou,et al.  External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer , 2014, World Journal of Urology.

[13]  A. Horwich,et al.  Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Eggener,et al.  Critical Evaluation of Modified Templates and Current Trends in Retroperitoneal Lymph Node Dissection , 2013, Current Urology Reports.

[15]  S. Fosså,et al.  Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  L. Kavoussi,et al.  Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. , 2012, The Journal of urology.

[17]  A. Horwich,et al.  2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  B. Carver,et al.  The role of lymphadenectomy for testicular cancer: indications, controversies, and complications. , 2011, The Urologic clinics of North America.

[19]  S. Fosså,et al.  Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Daneshmand,et al.  Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Einhorn,et al.  Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Schwartz,et al.  NCCN clinical practice guidelines in oncology: testicular cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  Owen Kang,et al.  Growing teratoma syndrome , 2008, International Journal of Gynecological Cancer.

[24]  W. Brenner,et al.  The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. , 2008, The Journal of urology.

[25]  R. Motzer,et al.  Medical treatment of advanced testicular cancer. , 2008, JAMA.

[26]  R. Motzer,et al.  Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Kavoussi,et al.  Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. , 2007, Urology.

[28]  R. Motzer,et al.  Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Einhorn,et al.  Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? , 2007, Cancer.

[30]  S. Culine,et al.  Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  B. Carver,et al.  Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. , 2007, Urology.

[32]  R. Motzer,et al.  Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. , 2007, The Journal of urology.

[33]  B. Czerniak,et al.  Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer , 2006, Cancer.

[34]  R. Motzer,et al.  Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. , 2006, The Journal of urology.

[35]  J. Bacik,et al.  Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Bacik,et al.  Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Motzer,et al.  Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. , 2005, The Journal of urology.

[38]  C. Bokemeyer,et al.  FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. , 2005, European journal of radiology.

[39]  S. Fosså,et al.  Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Aparicio,et al.  Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Koch,et al.  Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. , 2004, The Journal of urology.

[42]  R. Fimmers,et al.  Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. , 2004, The Journal of urology.

[43]  J. Sheinfeld,et al.  The role of retroperitoneal lymph node dissection in the management of testicular cancer. , 2004, Urologic oncology.

[44]  M. D. De Santis,et al.  The role of positron emission tomography in germ cell cancer , 2004, World Journal of Urology.

[45]  C. Bokemeyer,et al.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Bacik,et al.  Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Kantoff,et al.  Chemotherapy for teratoma with malignant transformation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Culine,et al.  Advanced seminoma—Treatment results and prognostic factors for survival after first‐line, cisplatin‐based chemotherapy and for patients with recurrent disease , 2003, Cancer.

[49]  D P Dearnaley,et al.  Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  C. Meisner,et al.  Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  P. Biron,et al.  Management of post-chemotherapy residual masses in advanced seminoma. , 2002, The Journal of urology.

[52]  P. Warde,et al.  Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. , 2002, The Canadian journal of urology.

[53]  L. Kiemeney,et al.  The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours , 2002, BJU international.

[54]  A. Pollack,et al.  Radiotherapy for stage II testicular seminoma. , 2001, International journal of radiation oncology, biology, physics.

[55]  A. Horwich,et al.  Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  G. Bartsch,et al.  Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. , 2000, The Journal of urology.

[57]  L. Weissbach,et al.  RPLND or Primary Chemotherapy in Clinical Stage IIA/B Nonseminomatous Germ Cell Tumors? , 2000, European Urology.

[58]  L. Einhorn,et al.  Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. , 2000, European journal of cancer.

[59]  R. Günther,et al.  Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. , 1999, Urology.

[60]  P. Albers,et al.  Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. , 1999, Urology.

[61]  Jewett Ma,et al.  Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. , 1998 .

[62]  L. Einhorn,et al.  Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  S. Culine,et al.  Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience. , 1998, European journal of cancer.

[64]  R. Motzer,et al.  Testicular germ-cell cancer. , 1997, The New England journal of medicine.

[65]  R. Motzer,et al.  Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  P. Carroll,et al.  A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. , 1997, International journal of radiation oncology, biology, physics.

[67]  L. Einhorn,et al.  Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  R. Motzer,et al.  Surgery for a post-chemotherapy residual mass in seminoma. , 1997, The Journal of urology.

[69]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[71]  S. Culine,et al.  Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. , 1997, British journal of urology.

[72]  R. Motzer,et al.  Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Thornhill,et al.  Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. , 1995, European journal of cancer.

[74]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  G. Kerr,et al.  Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. , 1995, The British journal of radiology.

[76]  L. Einhorn,et al.  Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Donohue,et al.  Complications of primary retroperitoneal lymph node dissection. , 1994, The Journal of urology.

[78]  N. Geller,et al.  Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  J. Thornhill,et al.  Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. , 1993, The Journal of urology.

[80]  P. Sogani Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. , 1991, The Urologic clinics of North America.

[81]  L. Einhorn,et al.  Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  J. Kearsley,et al.  Radiotherapy for stage 2 testicular seminoma: the prognostic influence of tumor bulk. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  L. Einhorn,et al.  Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. , 1988, Annals of internal medicine.

[84]  M. Gospodarowicz,et al.  Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. , 1988, The Journal of urology.

[85]  D. Stablein,et al.  Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. , 1987, The New England journal of medicine.

[86]  L. Weissbach,et al.  Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. , 1987, The Journal of urology.

[87]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[88]  G. Bartsch,et al.  Nerve-preserving bilateral retroperitoneal lymphadenectomy: anatomical study and operative approach. , 1987, The Journal of urology.

[89]  G. Pizzocaro Retroperitoneal lymph node dissection in clinical stage IIA and IIB nonseminomatous germ cell tumours of the testis. , 1987, International journal of andrology.

[90]  R. Salvioni,et al.  Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. , 1985, The Journal of urology.

[91]  P. Lange,et al.  Fertility issues following therapy for testicular cancer. , 1984, Seminars in urology.

[92]  J. Donohue,et al.  Distribution of nodal metastases in nonseminomatous testis cancer. , 1982, The Journal of urology.

[93]  P. Lange,et al.  Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. , 1982, The Journal of urology.

[94]  J. Donohue,et al.  Complications of retroperitoneal lymph node dissection. , 1981, The Journal of urology.

[95]  D. Mcleod,et al.  Radiation therapy: a primary treatment modality for seminoma. , 1980, The Urologic clinics of North America.

[96]  S. Hajdu,et al.  Distribution of retroperitoneal lymph node metastases in testicular germinal tumors , 1974 .

[97]  F. Hinman THE OPERATIVE TREATMENT OF TUMORS OF THE TESTICLE: WITH THE REPORT OF THIRTY CASES TREATED BY ORCHIDECTOMY , 1914 .

[98]  J. Dobson,et al.  On the Injection of Lymphatics by Prussian Blue. , 1910, Journal of anatomy and physiology.

[99]  Y. Lotan,et al.  Impact of hospital case volume on testicular cancer outcomes and practice patterns. , 2018, Urologic oncology.

[100]  P. Maroto,et al.  Long-term toxicity of the treatment for germ cell-cancer. A review. , 2018, Critical reviews in oncology/hematology.

[101]  P. Albers,et al.  False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. , 2015, Urologic oncology.

[102]  G. Bosl,et al.  Surgery of Testicular Tumors , 2012 .

[103]  P. Albers,et al.  Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. , 2009, European urology.

[104]  C. Catton,et al.  Management of stage II seminoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  M. Jewett,et al.  Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. , 1998, Seminars in oncology.

[106]  R. Motzer,et al.  Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. , 1998, The Journal of urology.

[107]  R. Motzer,et al.  Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  D. Dearnaley,et al.  Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. , 1994, The Journal of urology.

[109]  J. Donohue,et al.  Stage A nonseminomatous testis carcinoma: rationale and results of nerve-sparing retroperitoneal lymphadenectomy. , 1991, Urologia internationalis.

[110]  S. Fosså,et al.  Unilateral retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumor in clinical stage I. , 1984, European urology.

[111]  E. Sayegh,et al.  Roentgenographic visualization of human testicular lymphatics: a preliminary report. , 1963, The Journal of urology.